Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
October 16, 2007

Alte Biosciences Licenses Technology for Depression Drugs from Duke

  • Alte Biosciences secured exclusive rights to IP developed at the Duke University Medical Center for drugs targeting late-onset depression and related disorders.

    The licensed technology is a patent based on findings by Ranga Krishnan, M.D., related to the relationship between cerebrovascular disease and the onset of depression in elderly individuals, a disease called vascular depression. Dr. Krishnan is professor and chairman of the department of psychiatry and behavioral sciences at Duke University Medical Center.

    The company will immediately focus on conducting the regulatory studies needed to advance the lead candidate, ARX-111, into a clinical proof-of-concept study within the next 12 months, according to Thomas Colatsky, Ph.D., CSO for Alte Biosciences.

  • You’re all set! Thank you for subscribing to GEN Highlights.